# Unicet

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unicet

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.unicetbio.com/
- Total disclosed funding: $30M
- Latest round: Series A (Jun 12, 2026)
- Investors on record: 7

## About

Founded in 2018 and based in Beijing, China, Beijing Unicet Biotechnology Co., Ltd., trading as Unicet, is a biotech company that focuses on the development of cell drugs. 
In June 2026, Unicet raised nearly CNY 200 million in series A funding from Shenzhen Capital Real Estate Fund, Shunxi Fund, Zhongguancun Development Venture, and Lapam Capital, Flyfot Ventures.

The company focuses on developing innovative immune drugs based on ?d T cells and deeply explores the therapeutic potential of ?d T cell/BTN immune mechanisms in the fields of cancer, infectious diseases and autoimmune diseases. 

The company generates revenue from the R&D of cell drugs.

The company will use the latest funding for clinical research of core products, proof-of-concept for early-stage innovative pipelines, and continuous iteration and upgrading of the company's proprietary ?d T cell technology platform.

## Funding rounds

- Series A, Jun 12, 2026, $30M — Lapam Capital, Shenzhen Capital Real Estate Fund, Zhongguancun Development Venture, Shunxi Fund, Flyfot Ventures
- Series A, Jul 21, 2025 — Flyfot Ventures
- Angel, May 21, 2019 — Beijing Tongfang Yiheng Asset Management, Bugu Tianque Investmnet

## Investors

- Beijing Tongfang Yiheng Asset Management (https://capitalatlas.ai/funds/beijing-tongfang-yiheng-asset-management) — Angel
- Bugu Tianque Investmnet — Angel
- Flyfot Ventures (https://capitalatlas.ai/funds/flyfot-ventures) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Zhongguancun Development Venture (https://capitalatlas.ai/funds/zhongguancun-development-venture) — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A